Accelerate to discover

Back to filter

Related topics

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that...

Jun 20, 2021

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

Jun 4, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

Jun 3, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell washer that enable automated...

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

Jun 3, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest quality and precision and...

Jun 20, 2021

Cytek webinar : Evaluating Spectral Cytometry for Immune Profiling in Viral Disease

Cytek Biosciences

May 13, 2021

In conventional fluorescence cytometry, each fluorophore in a panel is measured in a target detector, through the use...

Show all topics (10)

MRI used to determine role of artificial sweeteners in pancreatic cancer disease progression

Jun 13, 2017

Pancreatic cancer has a remarkably high mortality rate, primarily due to late detection of the disease (Siegel et al. 2016). Therefore, efforts to reduce the incidence of pancreatic cancer may provide significant benefit in people at risk of developing the disease. Obese and diabetic individuals are known to have an increased risk of pancreatic cancer (Bardeesy et al. 2002).
Therefore, this study sought to determine whether aspartame or stevia, two commonly used artificial sweeteners, provide benefit in mice with pancreatic cancer. Lead author Dr. James Dooley and colleagues at the University of Leuven in Belgium published their paper entitled, “No Effect of Dietary Aspartame or Stevia on Pancreatic Acinar Carcinoma Development, Growth, or Induced Mortality in a Murine Model,” in Frontiers of Oncology in February of 2017.
The role of artificial sweeteners in cancer risk remains controversial (Tandel 2011), with some studies proposing anti-tumor effects while others purport carcinogenic properties of these chemicals. “With strong links to diabetes, glucose consumption and obesity, pancreatic cancer remains one of the strongest candidates to detect an oncogenic role, either promoting or suppressive, of artificial sweeteners,” the authors begin.
In order to test the potential role of these artificial sweeteners in pancreatic cancer disease progression, the authors allowed mice to drink water with or without aspartame or stevia present. The researchers used a Bruker Biospin 9.4 T Biospec small animal MR scanner to perform magnetic resonance imaging (MRI) in order to locate tumors in the mice and follow their progression over time.

Read more

Scientific paper
Application

Related technologies: Magnetic resonance imaging

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Bruker’s easy-to-use and cryogen-free high-performance compact MRI desktop system brings MRI within everyone’s reach

show detail

Multi-purpose high field MRI/MRS research systems, designed for the preclinical imaging and molecular MRI

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey